SIR-Spheres Radiation Microspheres Outperform Chemo in Liver Cancer Trial
SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than Nexavar in a Phase 3 trial.
Daniela Semedo, PhD, — 
Articles by Daniela Semedo
Albireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…
Monkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in…
New Study Is Examining How Doctors Manage Patients with Liver Disease
A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL). TARGET PharmaSolutions is conducting the…
Bozitinib Suppresses Liver Tumor Growth in Lab Setting, Study Shows
Bozitinib (CBT-101) suppresses the growth of human liver tumors in a laboratory environment, according to its maker, CBT Pharmaceuticals. The oral therapy works by…
Conatus Discusses Its Liver Disease Therapy Emricasan at Two New York Events
Conatus Pharmaceuticals updated participants at two New York medical conferences this month on  its efforts to develop emricasan, which has been shown to improve manifestations…
CymaBay Continues Development of Seladelpar for Liver Disease as Interim President, CEO Named
CymaBay Therapeutics has named Sujal Shah as interim president and CEO following the retirement of Harold Van Wart, PhD. Robert Wills, PhD, will serve as executive…